IN VIVO MODELS

• Calvaria periosteal injection for assessing effects on bone formation or resorption capability or both
• Dietary alterations for body composition and bone mineral density
• Estrogen-deficient bone loss for screening anti-resorption or anabolic agents
• Steroid-induced bone loss for seeking agents of osteopenia antagonist

• Bone safety for evaluating therapeutic effects on skeletal integrity, short or long term.
• Disuse bone loss for examining anti-resorptive and anabolic agents.
• Dietary alterations for body composition and effects on bone mineral density.
• Estrogen deficient bone loss for screening anti-resorptive and anabolic agents.
• Steroid-induced bone loss for seeking agents of osteopenia antagonist.
• Testosterone deficient bone loss for screening anti-resorptive and anabolic agents.

• PD/PK of dose range and short term effects on biomarkers of bone.
• Estrogen deficient bone loss for screening therapeutic effects on biomarkers of bone.
• Bone safety for evaluating therapeutic effects on skeletal integrity, long term with biopsies.

 EX VIVO PROCEDURES

• Biomechanics of bone properties
• Serum and urine biomarkers of bone remodeling
• Densitometry using pDEXA, and pQCT on bone mineral, micro-CT of 3-D structures
• Static and dynamic histomorphometry of bone cells and tissue, and quality of bone matrix